| Drug Name |
Isradipine |
| Drug ID |
BADD_D01216 |
| Description |
Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affinity and specificity and inhibits calcium flux into cardiac and arterial smooth muscle cells. It exhibits greater selectivity towards arterial smooth muscle cells owing to alternative splicing of the alpha-1 subunit of the channel and increased prevalence of inactive channels in smooth muscle cells. Isradipine may be used to treat mild to moderate essential hypertension. |
| Indications and Usage |
For the management of mild to moderate essential hypertension. It may be used alone or concurrently with thiazide-type diuretics. |
| Marketing Status |
approved; investigational |
| ATC Code |
C08CA03 |
| DrugBank ID |
DB00270
|
| KEGG ID |
D00349
|
| MeSH ID |
D017275
|
| PubChem ID |
3784
|
| TTD Drug ID |
D0Z7KE
|
| NDC Product Code |
42806-264; 64850-910; 64850-911; 69988-0012; 42291-062; 53069-0630; 16252-539; 42806-263; 16252-540; 50384-0120 |
| UNII |
YO1UK1S598
|
| Synonyms |
Isradipine | Isradipine, (+-)-Isomer | Isradipine, (R)-Isomer | PN-205-033 | PN 205 033 | PN205033 | PN 205-033 | PN 205033 | Lomir | PN 200-110 | PN-200-110 | PN 205-034 | PN 205 034 | PN 205034 | PN-205-034 | PN205034 | Dynacirc | Isradipine, (S)-Isomer |
